[go: up one dir, main page]

AU3270301A - Combined pde3 and pde4 inhibitor therapy for the treatment of obesity - Google Patents

Combined pde3 and pde4 inhibitor therapy for the treatment of obesity

Info

Publication number
AU3270301A
AU3270301A AU32703/01A AU3270301A AU3270301A AU 3270301 A AU3270301 A AU 3270301A AU 32703/01 A AU32703/01 A AU 32703/01A AU 3270301 A AU3270301 A AU 3270301A AU 3270301 A AU3270301 A AU 3270301A
Authority
AU
Australia
Prior art keywords
obesity
treatment
pde4 inhibitor
inhibitor therapy
pde3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32703/01A
Inventor
Peter Snyder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of AU3270301A publication Critical patent/AU3270301A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU32703/01A 1999-11-13 2000-11-13 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity Abandoned AU3270301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16541899P 1999-11-13 1999-11-13
US60165418 1999-11-13
PCT/US2000/042137 WO2001035979A2 (en) 1999-11-13 2000-11-13 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity

Publications (1)

Publication Number Publication Date
AU3270301A true AU3270301A (en) 2001-05-30

Family

ID=22598815

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32703/01A Abandoned AU3270301A (en) 1999-11-13 2000-11-13 Combined pde3 and pde4 inhibitor therapy for the treatment of obesity

Country Status (2)

Country Link
AU (1) AU3270301A (en)
WO (1) WO2001035979A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051502A1 (en) * 2000-12-22 2002-07-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combined inhibition of phosphodiesterase-4 (pde-4) and phosphodiesterase-3 (pde-3) as a therapy for th1-mediated autoimmune diseases
JP2004536614A (en) 2001-08-01 2004-12-09 ユニバーシティ オブ ユタ PDE3 cyclic nucleotide phosphodiesterase isoform-selective inhibitors and activators
FR2849594B1 (en) * 2003-01-03 2006-10-27 Oreal USE OF ZARDAVERINE AS SLIMMING
MXPA06002521A (en) 2003-09-05 2006-06-20 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus.
JP2008523127A (en) * 2004-12-14 2008-07-03 メナリーニ リチェルケ ソシエタ ペル アチオニ Pharmaceutical composition for the treatment of cellulite
WO2006094933A1 (en) 2005-03-08 2006-09-14 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
AU2007293885A1 (en) 2006-09-07 2008-03-13 Takeda Gmbh Combination treatment for diabetes mellitus
JPWO2009154230A1 (en) * 2008-06-17 2011-12-01 持田製薬株式会社 Non-alcoholic steatohepatitis prevention / improvement / treatment drug
US20130172356A1 (en) * 2010-06-23 2013-07-04 Kyushu University, National University Corporation Combination of egcg or methylated egcg and a pde inhibitor
US20150359798A1 (en) * 2011-09-06 2015-12-17 Jansfat Biotechnology Co., Ltd. Piperazinyl derivative reduces high-fat diet-induced accumulation of fat in the livers, therapeutically
RU2748294C2 (en) 2016-06-03 2021-05-21 Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк Method for treatment of prader-willi syndrome
US20210386743A1 (en) * 2018-10-08 2021-12-16 The Johns Hopkins University Use of pde9 inhibitors for treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014239A1 (en) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Composition for treating diabetes mellitus and obesity

Also Published As

Publication number Publication date
WO2001035979A3 (en) 2002-01-03
WO2001035979A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
PL362477A1 (en) Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2002259130A1 (en) Agents for treatment of hcv and methods of use
AU2001269314A1 (en) Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
AU2001265253A1 (en) Treatment of hiv using hyperthermia
AU2002237667A1 (en) Methods for the treatment and prevention of urinary stone disease
AU6435398A (en) Prevention and treatment of hepatocellular cancer
AU3270301A (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU5908300A (en) Prevention and treatment of amyloid-associated disorders
AU3960801A (en) Gear and procedure of achievement
AU7601400A (en) Treatment and prevention of hepatic disorders
AU2001255521A1 (en) Biphasic reaction vessel and methods of use
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
AU2432001A (en) Treatment of mental conditions including depression
AU3760900A (en) Treatment of menstrual function
AU2002222125A1 (en) Prevention and treatment of tachyphylactic response
AU2566201A (en) Compounds and methods for the treatment of pain
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase